Displaying 8 (all) recruiting clinical trials.
-
Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer
The purpose of this study is to better understand how well Cryo Ablation treats prostate cancer and the long-term effects of this treatment of sexual ... -
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
The purpose of the trial is to determine whether Darolutamide plus radiation therapy (RT) is non-inferior to gonadotropin releasing hormone (GnRH) agonist and bicalutamide plus ... -
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER [Regeneron 5678-ONC-1879]
The purpose of the trial is to determine safety and tolerability of REGN5678 alone and in combination with cemiplimab in treatment-experienced metastatic castration-resistant prostate cancer ... -
A Phase 1 and 2a trial of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer
The purpose of the study is to determine and investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-1207, a bi-specific antibody ... -
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
This study wants to find out if a new way of treating prostate cancer is safe and possible. They will use a special kind of ...
-
Prospective Multicenter Single-Arm Study of VanquishTM Water Vapor Ablation for Prostate Cancer
This study will look at how well the Vanquish Water Vapor Ablation Device works to treat people with Gleason Grade Group 2 (GGG2) localized intermediate-risk ...
-
PRostate Cancer Treatment with the AQUABEAM Robotic System
This study is testing a special machine called the AQUABEAM Robotic System. This machine is designed to treat cancer tissue in the prostate. It does ...
-
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
This study wants to see if a new immunotherapy treatment called ONC-392, combined with Lu 177 vipivotide (Pluvicto) compared to Lu 177 vipivotide (Pluvicto) alone ...